SecBot SecBot
425 ·Filed Sep 9, 2026

INM

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 6/10
Horizonweeks Processed2mo ago SEC0001213900-26-098432
Rule 425 M&A communications
Actionable Insight • Neutral

INM is a $4M market-cap shell whose value is purely a function of the Mentari merger closing. The FY2026 results confirm the company has no standalone path, cash is $2.2M with $1.8M in payables. Monitor for Form S-4 effectiveness and shareholder vote dates; deal failure would likely render INM equity worthless. The ~$490M pre-closing financing by Mentari provides a strong signal of institutional backing, but INM holders will be diluted into a small stub position in the combined entity.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$1.31
T+0 close · Sep 9, 2026 · via day close
Latest settled
+1.53%
T+20 · $1.33 · next T+60 in 17d
Vs SPY
−0.60%
α at T+20
Latest observation
+69.66%
T+46 · FF3 residual α
  1. T+0 · Sep 10 $1.31entry
  2. T+1 · 2mo ago −1.53%α −2.38% · $1.29
  3. T+5 · 2mo ago +6.11%α +6.61% · $1.39
  4. T+20 · 6w ago +1.53%α −0.60% · $1.33
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals filed a Rule 425 communication reporting FY2026 annual results and providing a corporate update on its proposed merger with Mentari Therapeutics. The net loss widened to $12.6M from $8.2M, cash burned to $2.2M, and the company is a pre-revenue shell whose value is entirely tied to the pending reverse-merger into Mentari, which has raised ~$490M in pre-closing financing. The merger remains on track for Q4 2026 close, but InMed's standalone financials show a deteriorating cash position and no operating revenue, making this a binary event on deal completion.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Net loss widened to $12.6M for FY2026 vs $8.2M in FY2025
  • Cash and short-term investments fell to $2.2M from $10.7M year-over-year
  • Merger with Mentari Therapeutics on track for Q4 2026 close; combined company to trade as MTRI
  • Mentari raised ~$490M total pre-closing financing ($290M May + $200M July 2026)
  • InMed's legacy pipeline (INM-901, INM-089, INM-755) to be monetized via CVR structure
  • BayMedica subsidiary discontinued and wound down
  • Form S-4 filed but not yet effective; shareholder votes pending

Financial Impact

Net loss of $12.6M on $0 revenue from continuing operations; cash burn of $8.6M from operations; cash runway effectively zero without merger proceeds

revenuenet_incomecashshareholder_equity

Risk Factors

  • Merger fails to close, InMed has no revenue and insufficient cash to continue operations
  • Shareholder or stockholder approval not obtained
  • Form S-4 not declared effective by SEC
  • Legacy InMed pipeline (CVRs) may never generate value
  • Nasdaq continued-listing requirements may not be met

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
425 Filing (Primary)0001213900-26-098432
Document: 0001213900-26-098432-index-headers.html0001213900-26-098432
Document: 0001213900-26-098432-index.html0001213900-26-098432
Document: 0001213900-26-098432.txt0001213900-26-098432

Track record

22 reports on INM

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 10 of 12 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  3. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
  4. Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
  5. Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
  6. Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
  7. Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
  8. Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
  9. Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
  10. Sep 9, 20269w ago 425 Neutral 6/10 Viewing Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026